NCT03168711View on ClinicalTrials.gov

Safety of Urate Elevation in Amyotrophic Lateral Sclerosis (ALS)

PHASE2CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

October 1, 2017

Primary Completion Date

December 10, 2019

Study Completion Date

January 7, 2020

Conditions
Amyotrophic Lateral Sclerosis
Interventions
DRUG

Inosine

Subjects on inosine will receive 1-6 capsules a day of 500 mg inosine titrated to target urate levels of 7 - 8 mg/dL.

DRUG

Placebo

Subjects on placebo will receive 1-6 capsules a day of 500 mg placebo (sugar pill) titrated to target urate levels of 7 - 8 mg/dL.

Trial Locations (3)

33308

Holy Cross Hospital, Fort Lauderdale

55455

University of Minnesota, Minneapolis

02114

Massachusetts General Hospital, Boston

All Listed Sponsors
collaborator

The Salah Foundation

OTHER

collaborator

Sean M. Healey & AMG Center for ALS

OTHER

lead

Massachusetts General Hospital

OTHER

NCT03168711 - Safety of Urate Elevation in Amyotrophic Lateral Sclerosis (ALS) | Biotech Hunter | Biotech Hunter